DE602004022170D1 - 2-imino-4-(thio)oxo-5-polycyclovinylazoline zur verwendung als pi3-kinase-inhibtoren - Google Patents

2-imino-4-(thio)oxo-5-polycyclovinylazoline zur verwendung als pi3-kinase-inhibtoren

Info

Publication number
DE602004022170D1
DE602004022170D1 DE602004022170T DE602004022170T DE602004022170D1 DE 602004022170 D1 DE602004022170 D1 DE 602004022170D1 DE 602004022170 T DE602004022170 T DE 602004022170T DE 602004022170 T DE602004022170 T DE 602004022170T DE 602004022170 D1 DE602004022170 D1 DE 602004022170D1
Authority
DE
Germany
Prior art keywords
polycyclovinylazoline
imino
thio
oxo
kinase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004022170T
Other languages
German (de)
English (en)
Inventor
Thomas Rueckle
Jeffrey Shaw
Dennis Church
David Covini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Merck Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono SA filed Critical Merck Serono SA
Publication of DE602004022170D1 publication Critical patent/DE602004022170D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DE602004022170T 2003-07-28 2004-07-27 2-imino-4-(thio)oxo-5-polycyclovinylazoline zur verwendung als pi3-kinase-inhibtoren Expired - Lifetime DE602004022170D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03102313 2003-07-28
PCT/EP2004/051625 WO2005011686A1 (en) 2003-07-28 2004-07-27 2-imino-4-(thio) oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors

Publications (1)

Publication Number Publication Date
DE602004022170D1 true DE602004022170D1 (de) 2009-09-03

Family

ID=34112474

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004022170T Expired - Lifetime DE602004022170D1 (de) 2003-07-28 2004-07-27 2-imino-4-(thio)oxo-5-polycyclovinylazoline zur verwendung als pi3-kinase-inhibtoren

Country Status (9)

Country Link
US (1) US8106214B2 (https=)
EP (1) EP1648452B1 (https=)
JP (1) JP4908210B2 (https=)
CA (1) CA2531140C (https=)
DE (1) DE602004022170D1 (https=)
ES (1) ES2328146T3 (https=)
IL (1) IL173195A (https=)
NO (1) NO332434B1 (https=)
WO (1) WO2005011686A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1718642A4 (en) * 2004-02-25 2010-11-24 Glaxosmithkline Llc NEW CHEMICAL COMPOUNDS
MXPA06015028A (es) 2004-07-01 2007-02-08 Hoffmann La Roche Tiazolinas cinolinas no sustituidas.
CN101052640B (zh) * 2004-09-03 2011-05-11 默克雪兰诺有限公司 吡啶亚甲基唑烷酮类及其作为磷酸肌醇抑制剂的用途
US7241893B2 (en) 2004-09-17 2007-07-10 Hoffman-La Roche Inc. Thiazolinone 2-substituted quinolines
US7253285B2 (en) 2004-09-17 2007-08-07 Hoffmann-La Roche Inc. Thiazolinone 4-monosubstituted quinolines
CN101039939B (zh) * 2004-10-14 2010-07-07 霍夫曼-拉罗奇有限公司 作为cdk1抑制剂的喹唑啉基亚甲基噻唑啉酮类
US7304074B2 (en) * 2005-04-05 2007-12-04 Hoffmann-La Roche Inc. Substituted 1,5-naphthyridine azolinones
PE20070083A1 (es) * 2005-06-08 2007-01-27 Smithkline Beecham Corp (5z)-5-(6-quinoxalinilmetilideno)-2-[(2,6-diclorofenil)amino]-1,3-tiazol-4(5h)-ona
CN101300047A (zh) * 2005-09-07 2008-11-05 雪兰诺实验室有限公司 Pi3k抑制剂用于子宫内膜异位症的治疗
US20080306057A1 (en) * 2005-10-11 2008-12-11 Laboratories Serono Sa P13K Inhibitors for the Treatment of Endometriosis
EP1976495A2 (en) * 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
WO2007113005A2 (en) * 2006-04-03 2007-10-11 European Molecular Biology Laboratory (Embl) 2-substituted 3-aminosulfonyl-thiophene derivatives as aurora kinase inhibitors
CL2007000995A1 (es) * 2006-04-11 2008-06-27 Smithkline Beecham Corp Compuestos derivados de tiazolidinadiona; composicion farmaceutica; y uso para tratar uno o mas estados de enfermedad seleccionada entre trastornos autoinmunes, enfermedad inflamatoria, cardiovascular y neurodegenerativa entre otras.
US20100286041A1 (en) * 2007-03-22 2010-11-11 Smithkline Beecham Corporation (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one
US20080255115A1 (en) * 2007-04-11 2008-10-16 Michael Gerard Darcy Thiazolidinedione derivatives as pi3 kinase inhibitors
PE20090288A1 (es) * 2007-05-10 2009-04-03 Smithkline Beecham Corp Derivados de quinoxalina como inhibidores de la pi3 quinasa
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
FR2919608B1 (fr) * 2007-08-01 2012-10-05 Univ Rennes Derives d'imidazolones,procede de preparation et applications biologiques
EP2255830A1 (en) 2008-03-03 2010-12-01 Takeda Pharmaceutical Company Limited Concomitant drug
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
MX2013000617A (es) * 2010-07-16 2013-06-13 Piramal Entpr Ltd Derivados sustituidos de imidazoquinolina como inhibidores de quinasa.
CN102584809B (zh) * 2011-01-14 2014-12-24 湘北威尔曼制药股份有限公司 胺基噻唑烷酮化合物及其制备方法与在制备抗肿瘤药物中的应用
US9745323B2 (en) 2012-07-30 2017-08-29 Kyoto University Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor
US10310802B2 (en) * 2014-03-26 2019-06-04 Unanimous A. I., Inc. System and method for moderating real-time closed-loop collaborative decisions on mobile devices
CN106588909B (zh) * 2017-01-06 2019-08-27 广东工业大学 一种喹啉类衍生物的制备及其在抗炎中的应用
HRP20240793T1 (hr) 2018-04-18 2024-09-13 Constellation Pharmaceuticals, Inc. Modulatori enzima koji modificiraju metil, njihovi pripravci i upotreba
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
LT4003532T (lt) 2019-07-24 2024-11-11 Constellation Pharmaceuticals, Inc. 7-chlor-2- (4-(3-metoksiazetidin-1-il)cikloheksil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-okso-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioksol-5-karboksamido kristalinės formos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH052200A (ja) 1990-09-28 1993-01-08 Toshiba Corp 有機非線形光学材料
JP3871354B2 (ja) * 1994-07-29 2007-01-24 株式会社フジモト・コーポレーション 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体
JP4782564B2 (ja) 2002-07-10 2011-09-28 メルク セローノ ソシエテ アノニム アゾリジノン−ビニル縮合−ベンゼン誘導体
CN100579978C (zh) * 2002-11-22 2010-01-13 史密丝克莱恩比彻姆公司 化合物
CN101052640B (zh) 2004-09-03 2011-05-11 默克雪兰诺有限公司 吡啶亚甲基唑烷酮类及其作为磷酸肌醇抑制剂的用途

Also Published As

Publication number Publication date
EP1648452A1 (en) 2006-04-26
JP2007500171A (ja) 2007-01-11
EP1648452B1 (en) 2009-07-22
NO20060573L (no) 2006-02-03
US20070021447A1 (en) 2007-01-25
JP4908210B2 (ja) 2012-04-04
AU2004260836A1 (en) 2005-02-10
US8106214B2 (en) 2012-01-31
IL173195A (en) 2013-04-30
CA2531140A1 (en) 2005-02-10
NO332434B1 (no) 2012-09-17
ES2328146T3 (es) 2009-11-10
IL173195A0 (en) 2006-06-11
WO2005011686A1 (en) 2005-02-10
CA2531140C (en) 2013-06-18

Similar Documents

Publication Publication Date Title
DE602004022170D1 (de) 2-imino-4-(thio)oxo-5-polycyclovinylazoline zur verwendung als pi3-kinase-inhibtoren
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
ATE492544T1 (de) Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
CY2013014I1 (el) Εναντιομερικως καθαρες αμινοετεροαρυλικες ενωσεις ως αναστολεις πρωτεϊνικης κινασης
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
AP2114A (en) Aminoheteroaryl compounds as protein kinase inhibitors
DE602007014374D1 (de) Ä4,5'ü-bipyrimidinyl-6,4'-diaminderivate als proteinkinase-hemmer
ATE524467T1 (de) Neuartige aza-heterozyklen als kinase-inhibitoren
IL173380A0 (en) Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
ATE505471T1 (de) Azaindol-kinaseinhibitoren
ATE518860T1 (de) Pyrroloä2,3-büpyridinderivate als proteinkinaseinhibitoren
ATE479434T1 (de) Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
ZA200709269B (en) Protein kinase inhibitors
ATE530545T1 (de) Als kinaseinhibitoren geeignete pyrazolylaminopyridinderivate
PL378116A1 (pl) Heterocykliczne inhibitory kinazy
ATE509011T1 (de) Pyrimidinderivate als 11beta-hsd1-inhibitoren
DE60322544D1 (de) Glycinamid-derivate als raf-kinase-hemmer
DE602004026905D1 (de) 2-aminoaryloxazol-verbindungen als tyrosinkinase-hemmer
DK1943243T3 (da) Kinase-inhibitorer
ATE433449T1 (de) Kinaseinhibitoren
SI2476667T1 (sl) Aminoheteroarilne spojine kot inhibitorji protein-kinaze
ATE302781T1 (de) Sulfamidothienopyrimidine zur verwendung als phosphodiesterase v-hemmer
ZA200703835B (en) Heterocyclic substituted bisarylurea derivatives as kinase inhibitors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition